Last reviewed · How we verify
fluoxetine or desipramine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
fluoxetine or desipramine (fluoxetine or desipramine) — National Institute of General Medical Sciences (NIGMS).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| fluoxetine or desipramine TARGET | fluoxetine or desipramine | National Institute of General Medical Sciences (NIGMS) | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- fluoxetine or desipramine CI watch — RSS
- fluoxetine or desipramine CI watch — Atom
- fluoxetine or desipramine CI watch — JSON
- fluoxetine or desipramine alone — RSS
Cite this brief
Drug Landscape (2026). fluoxetine or desipramine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoxetine-or-desipramine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab